The company credited the increased revenue to sales from the MammoView line, as well as increased orders for the company’s vascular clamp system. European vendors made inventory purchases in the second and third quarter when the dollar increased in value against the Euro.
Solos recently announced that the company completed a capital restructuring initiative to position itself for growth over the next 12 months.
Read the Trading Markets report on Solos Endoscopy.
Read more news on Solos Endoscopy:
–Solos Endoscopy Completes Capital Restructuring Initiatives
–Solos Endoscopy Reports 10% Increase in Revenue for Q1
–Solos Endoscopy Names New CFO
